[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
3. Zhao J, Yan LN, Li B: Adult-to-adult living donor liver transplantation for malignant metastatic melanoma to the liver. Hepatobiliary Pancreat Dis Int; 2010 Jun;9(3):329-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-to-adult living donor liver transplantation for malignant metastatic melanoma to the liver.
  • BACKGROUND: Metastases from malignant melanoma to the liver are rare in China, and surgical resection may be of potential benefit.
  • Liver transplantation for this disease has never been reported.
  • METHODS: We report a case of adult-to-adult living donor liver transplantation (A-A LDLT) for metastatic melanoma.
  • With a surgical history of ocular melanoma, the recipient presented with emaciation from a large right hepatic mass which also probably had portal vein invasion.
  • Postoperative pathology confirmed the diagnosis of metastatic malignant melanoma; however no adjuvant chemotherapy was employed after transplantation.
  • We also reviewed the literature on the surgical treatment of metastatic malignant melanoma to the liver and discussed the LDLT indications.
  • CONCLUSIONS: Review of the literature suggested that only a small subset of selected patients may benefit from liver resection.
  • Large metastatic disease in the liver potentially involving a major vessel, as in this case, should be contraindicated for liver transplantation.
  • [MeSH-major] Ciliary Body / pathology. Liver Neoplasms / surgery. Liver Transplantation. Living Donors. Melanoma / surgery. Uveal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors. Tomography, X-Ray Computed. Treatment Outcome


Advertisement
4. Ortner MA: [Klatskin tumors--diagnostic and interventional therapy]. Praxis (Bern 1994); 2006 Oct 18;95(42):1637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Klatskin tumors--diagnostic and interventional therapy].
  • [Transliterated title] Klatskin-Tumoren--Diagnostik und interventionelle Therapie.
  • Klatskin tumors are defined as malignant tumors of the bile duct involving the bifurcation and intrahepatic bile ducts.
  • Imaging procedures for diagnosis and staging are ultrasonography, magnetic resonance imaging with cholangiopancreaticography, intravenous bolus-enhanced spiral computed tomography and endoscopic retrograde cholangiopancreaticography.
  • Before initiating any palliative measure, a proper staging and a surgical consultation at a hepatobiliary center is necessary.
  • To assess resectability, additional diagnostic methods like angiography, positron emission tomography, cholangioscopy, endoscopic or intraluminal ultrasonography and finally even explorative laparoscopy may be required.
  • At time of diagnosis only a small percentage of Klatskin tumors is curative resectable.
  • Therefore, palliative treatment options play an important role.
  • Although it improves quality of life, it does not seem to improve survival time.
  • Definitive evidence for a benefit of additional radio and/or chemotherapy is still missing.
  • Photodynamic therapy, a light therapy, is the first approach leading to an improvement of cholestasis and quality of life as well as to a prolongation of survival time.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Hepatic Duct, Common. Klatskin Tumor / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111849.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H: Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):92-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
  • In malignancy, actively proliferating cells may be effectively targeted and killed by anti-cancer therapies, but stem cells may survive and support re-growth of the tumor.
  • Thus, new strategies for the treatment of cancer clearly will also have to target cancer stem cells.
  • Total RNA was isolated and real-time RT-PCR was performed to determine the expression of ABCG2 and CD133.
  • RESULTS: All pancreatic carcinoma cell lines tested expressed significantly higher levels of ABCG2 than non-malignant fibroblasts or two other malignant non-pancreatic cell lines, i.e., SaOS2 osteosarcoma and SKOV3 ovarian cancer.
  • Because cancer stem cells are thought to be responsible for tumor initiation and its recurrence after an initial response to chemotherapy, they may be a very promising target for new drug developments.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Adenocarcinoma / metabolism. Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Glycoproteins / biosynthesis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287174.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 Antigen; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


7. La Quaglia MP, Shorter NA, Blumgart LH: Central hepatic resection for pediatric tumors. J Pediatr Surg; 2002 Jul;37(7):986-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 3 received neoadjuvant chemotherapy before hepatic resection.
  • CONCLUSION: Central hepatic resection of malignant tumors involving segments IV, V, and VIII is feasible and effective in childhood.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Colorectal Neoplasms / pathology. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Infant. Male. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12077755.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Fan YZ, Fu JY, Zhao ZM, Chen CQ: Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):72-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gallbladder carcinoma is a lethal malignant neoplasm with dismal surgical results.
  • Unfortunately, the adjuvant therapies for gallbladder carcinoma such as chemotherapy and radiotherapy are also disappointing.
  • METHODS: Human gallbladder carcinoma GBC-SD cells were grown in cell culture and divided into a NCTD group and a control group.
  • RESULTS: NCTD inhibited the proliferation of GBC-SD cells in a dose- and time-dependent manner, with an IC50 of 56.18 microg/ml at 48 hours.
  • The flow cytometric profiles revealed that NCTD (at the IC50 for 48 hours) significantly increased the proportion of cells in G2/M phase and significantly decreased the proportion of cells in S phase, with a significantly increased rate of cell apoptosis.
  • After treatment with the 48-hour IC50 dose of NCTD, cell shrinkage, vacuolar cytoplasm, membrane budding, karyorrhexis, karyolysis, chromosome condensation and chromatin aggregation in some GBC-SD cells were observed by light-microscopy; decreased microvilli, Golgiosome atrophy, mitochondrial swelling, nuclear shrinkage, chromosome condensation and typical apoptosis bodies were seen by electron-microscopy, and the morphological changes of apoptosis occurred in GBC-SD cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Bicyclo Compounds, Heterocyclic / pharmacology. Cell Proliferation / drug effects. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Cell Cycle / drug effects. Humans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287171.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bicyclo Compounds, Heterocyclic; 5442-12-6 / norcantharidin
  •  go-up   go-down


9. Nestler G, Halloul Z, Evert M, Dombrowski F, Lippert H, Meyer F: Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern. J Hepatobiliary Pancreat Surg; 2007;14(2):197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myogenous sarcoma of the gallbladder with a hemangiopericytomatous pattern.
  • Primary sarcoma of the gallbladder is a very rare neoplasm, and there are few instances of its diagnostic and therapeutic management.
  • We describe a 66-year-old male patient with a sarcoma of the gallbladder.
  • He initially underwent a laparoscopic cholecystectomy, converted to an open procedure.
  • Histology showed a primary sarcoma of the gallbladder (NOS).
  • The two surgical interventions were done with no major complications, and a radical resection status was achieved.
  • Histological investigation revealed a malignant mesenchymal tumor lesion, which was classified as a myogenous sarcoma with a hemangiopericytomatous pattern.
  • Palliative chemotherapy was scheduled, but the patient died of advanced tumor recurrence 10 days after this diagnosis.
  • Despite a poor overall prognosis, extensive surgical resection is favored for myogeneous sarcoma of the gallbladder; this procedure is based on precise clarification of the histopathological diagnosis, and can be followed by attempts with radiation of chemotherapy if early diagnosis-finding has failed.
  • This approach allowed, in our patient with this rare neoplasm, a remarkable tumor-free survival of almost 1 year.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Aged. Cholecystectomy. Humans. Immunohistochemistry. Lymph Node Excision. Male. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384914.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One; 2008 Jul 09;3(7):e2637
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we report the isolation of CD133-positive cells (LC-CD133(+)) and CD133-negative cells (LC-CD133(-)) from tissue samples of ten patients with non-small cell lung cancer (LC) and five LC cell lines.
  • Furthermore, LC-CD133(+), unlike LC-CD133(-), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy.
  • The treatment of Oct-4 siRNA with lentiviral vector can specifically block the capability of LC-CD133(+) to form spheres and can further facilitate LC-CD133(+) to differentiate into LC-CD133(-).
  • Finally, in vitro and in vivo studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133(+) can be improved by the treatment of Oct-4 siRNA.
  • Future research is warranted regarding the up-regulated expression of Oct-4 in LC-CD133(+) and malignant lung cancer.
  • [MeSH-major] Antigens, CD / analysis. Glycoproteins / analysis. Lung Neoplasms / metabolism. Neoplastic Stem Cells / metabolism. Octamer Transcription Factor-3 / metabolism. Peptides / analysis
  • [MeSH-minor] AC133 Antigen. ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / metabolism. Apoptosis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Line, Tumor. Cell Survival. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jul 19;448(7151):313-7 [17554338.001]
  • [Cites] Respirology. 2007 Jul;12(4):471-7 [17587411.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):141-6 [18157115.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):30-4 [17932422.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):361-70 [14667503.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Nature. 1990 Jun 21;345(6277):686-92 [1972777.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12873-8 [8662786.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Mol Reprod Dev. 1998 Oct;51(2):218-24 [9740330.001]
  • [Cites] Cell. 1998 Oct 30;95(3):379-91 [9814708.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):104-12 [10077160.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1770-7 [15753373.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5410-6 [16061855.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):872-84 [16227977.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):291-301 [16450219.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):295-305 [18297062.001]
  • [Cites] PLoS One. 2008;3(5):e2090 [18509505.001]
  • [Cites] Biochem J. 2003 Oct 1;375(Pt 1):199-205 [12841847.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8085-91 [11781821.001]
  • [Cites] Trends Cell Biol. 2002 Sep;12(9):432-8 [12220864.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3052-7 [12912956.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9530-5 [16772384.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7 [17287174.001]
  • [Cites] PLoS One. 2007;2(2):e243 [17327908.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4137-45 [17827464.001]
  • (PMID = 18612434.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 Antigen; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / PROM1 protein, human; 0 / Peptides; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2440807
  •  go-up   go-down


11. Fais PO, Carricaburu E, Sarnacki S, Berrebi D, Orbach D, Baudoin V, de Lagausie P: Is laparoscopic management suitable for solid pseudo-papillary tumors of the pancreas? Pediatr Surg Int; 2009 Jul;25(7):617-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Solid pseudo-papillary tumors (SPT) are rare pancreatic neoplasms of low-malignant potential occurring mainly in young women.
  • Diagnosis or treatment was carried out using laparoscopic techniques (biopsy and resection in one case and biopsy only in two).
  • The two patients with peritoneal recurrences were treated by surgical resection and chemotherapy.
  • All three patients were alive at the time of this writing.
  • All three patients developed recurrences.
  • These poor results contrast sharply with the low risk of local or disseminated recurrence after open laparotomy without chemotherapy that has been considered as the treatment of choice up to now.
  • [MeSH-major] Cystadenoma, Papillary / diagnosis. Cystadenoma, Papillary / surgery. Laparoscopy / methods. Neoplasm Recurrence, Local / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1992-5 [17161189.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):456-9 [16109536.001]
  • [Cites] World J Surg. 1998 Jan;22(1):55-60; discussion 60-1 [9465762.001]
  • [Cites] Hepatogastroenterology. 2005 Nov-Dec;52(66):1889-94 [16334801.001]
  • [Cites] J Urol. 2003 Sep;170(3):932-5 [12913744.001]
  • [Cites] Eur J Radiol. 2006 Apr;58(1):132-9 [16377114.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):200-3 [18067066.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(10):789-93 [9587521.001]
  • [Cites] Arch Surg. 1994 Sep;129(9):897-9; discussion 900 [8080369.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):W178-86 [16861508.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):2028-31 [14598158.001]
  • [Cites] Acta Chir Iugosl. 2003;50(4):21-6 [15307493.001]
  • [Cites] JOP. 2007 Mar 10;8(2):223-7 [17356247.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] World J Surg. 2006 Oct;30(10 ):1916-9; discussion 1920-1 [16855802.001]
  • [Cites] Chirurg. 2004 Jun;75(6):615-21 [15103421.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1065-9 [17206487.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Chir. 2003 Sep;128(7):452-6 [14559194.001]
  • [Cites] Gastroenterol Clin Biol. 1999 Feb;23(2):207-14 [10353015.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):269-71 [12709760.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jan;19(1):89-94 [18192472.001]
  • [Cites] Diagn Cytopathol. 2005 Dec;33(6):421-8 [16389690.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Aug;5(3):454-8 [16911949.001]
  • [Cites] JOP. 2006 Nov 10;7(6):635-42 [17095844.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):9-14 [11176227.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] Pancreatology. 2006;6(4):291-6 [16636602.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):733-7 [16609955.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1243-9 [17001154.001]
  • (PMID = 19479267.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Vennarecci G, Ettorre GM, Giovannelli L, Del Nonno F, Perracchio L, Visca P, Corazza V, Vidiri A, Visco G, Santoro E: Solitary fibrous tumor of the liver. J Hepatobiliary Pancreat Surg; 2005;12(4):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the liver.
  • We report a new case of benign solitary fibrous tumor (SFT) of the liver.
  • Ultrasonography and computed tomography showed a large tumor, 20 cm in diameter, in the right lobe of the liver.
  • Microscopic evaluation showed a benign SFT of the liver with tumor cells typically positive for vimentin and CD34.
  • This is a rare neoplasm of mesenchymal origin that occasionally involves the liver in adult patients.
  • Most SFTs are benign, but some may have malignant histological features and recur locally or metastasize.
  • Surgery is the mainstay of treatment.
  • As SFT of the liver is often a benign neoplasm, chemotherapy or radiotherapy should not be necessary, and should be reserved for when resection is incomplete and/or histological examination reveals features of malignancy.
  • Surgeons must be aware of SFT of the liver, and this neoplasm should be included in the differential diagnosis of a single large hepatic mass.
  • [MeSH-major] Liver Neoplasms / pathology. Neoplasms, Fibrous Tissue / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133706.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S: Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol; 2003 Dec;52(6):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) are key enzymes for predicting the efficacy of 5-FU in the treatment of malignant tumors.
  • However, 5-FU is not commonly commonly chosen for chemotherapeutic treatment of hepatocellular carcinoma (HCC) in practice.
  • The aim of this study was to determine the activities of both DPD and TS in HCCs and corresponding liver parenchyma and to assess the correlation between the activities of these enzymes and clinicopathological features.
  • METHODS: The study material comprised 33 pairs of hepatocellular carcinoma and noncancerous liver samples.
  • The DPD and TS activities were quantified by a radiometric enzymatic assay and a 5-fluoro-2'-deoxyuridine-5'- monophosphate (FdUMP) ligand-binding assay, respectively.
  • DPD activity was lower in the HCCs regardless of their clinical features than in the noncancerous liver parenchyma, whereas TS activity was generally lower in HCCs except for those with certain clinical features.
  • HCCs with multiple nodules showed lower DPD activity and those with a diameter of more than 5 cm showed lower TS activity.
  • In the noncancerous liver parenchyma, a gradual decrease in DPD activity and an increase in TS activity were associated with the age of the patient, liver damage and z-factor.
  • CONCLUSIONS: DPD and TS activity may be affected by the clinicopathological status in both the HCC and the corresponding liver parenchyma.
  • Some HCC patients may be good candidates for 5-FU-based chemotherapy based on measurements of tumor levels of DPD and TS.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Liver / enzymology. Liver Neoplasms / enzymology. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Fluorouracil / therapeutic use. Hepatitis, Viral, Human / enzymology. Hepatitis, Viral, Human / pathology. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680162.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol; 2001 Dec;54(12):927-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium.
  • The activation of apoptosis is a major mode of action of chemotherapy and radiotherapy, which have limited benefit in the treatment of cholangiocarcinoma.
  • METHODS: The expression of Bcl-2, Bcl-X(L), and Mcl-1 was investigated in normal biliary epithelium (17), biliary dysplasia (three), and invasive cholangiocarcinoma (51), in addition to three human cholangiocarcinoma cell lines, by immunohistochemistry and immunofluorescence.
  • RESULTS: The expression of Bcl-2 was not detected in normal or malignant biliary tissue.
  • In contrast, granular cytoplasmic Bcl-X(L) and Mcl-1 staining was found in 60-100% of cells in all normal, dysplastic, and malignant specimens, including the human cell lines examined in this study.
  • CONCLUSION: These findings indicate that Mcl-1 and Bcl-X(L), but not Bcl-2, are involved in the survival of normal and neoplastic cells in the biliary tree.
  • By prolonging survival through blocking apoptosis, these proteins might be reducing the efficacy of cytotoxic anticancer treatments in cholangiocarcinoma.
  • [MeSH-major] Apoptosis / physiology. Bile Duct Neoplasms / chemistry. Cholangiocarcinoma / chemistry. Neoplasm Proteins / analysis. Precancerous Conditions / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1984 Jan 14;1(8368):66-70 [6197596.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:122-6 [10436802.001]
  • [Cites] J Hepatol. 1985;1(6):579-96 [4056357.001]
  • [Cites] Aust N Z J Surg. 1989 Jan;59(1):25-30 [2536540.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5407-11 [1394146.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):283-90 [1341262.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):460-5 [8129031.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2576-82 [7780971.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1389-94 [7478561.001]
  • [Cites] Tohoku J Exp Med. 1995 Sep;177(1):61-71 [8693487.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):975-8 [8687162.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4743-8 [8840993.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Annu Rev Neurosci. 1997;20:245-67 [9056714.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1845-53 [9058703.001]
  • [Cites] Australas Radiol. 1997 May;41(2):151-4 [9153812.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 Jun;106(6):445-50 [9199601.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):389-93 [9215121.001]
  • [Cites] Hepatology. 1997 Oct;26(4):884-90 [9328309.001]
  • [Cites] J Intern Med Suppl. 1997;740:139-45 [9350196.001]
  • [Cites] Blood. 1998 Feb 1;91(3):991-1000 [9446661.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):365-72 [9783782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6 [9843949.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):78-81 [10025387.001]
  • [Cites] Nature. 1999 Jun 3;399(6735):483-7 [10365962.001]
  • [Cites] Histopathology. 1999 Jun;34(6):497-501 [10383693.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):108-16 [10398896.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):122-7 [10398898.001]
  • [Cites] Swiss Surg. 1999;5(3):111-5 [10414181.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4495-504 [10442640.001]
  • (PMID = 11729212.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  • [Other-IDs] NLM/ PMC1731328
  •  go-up   go-down


15. Guo XL, Ma NN, Zhou FG, Zhang L, Bu XX, Sun K, Song JR, Li R, Zhang BH, Wu MC, Wei LX: Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep; 2009 Sep;22(3):549-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells.
  • The telomerase is specifically activated in most malignant tumors but is usually inactive in normal somatic cells.
  • Furthermore, preincubation of low-dose cisplatin which induced high expression of hTERT help hepatocellular carcinoma SMMC7721 cells survive under the high concentration of anti-cancer drugs.
  • Inhibition of hTERT increased sensitivity of SMMC7721 cells to chemotherapy.
  • Taken together, these results suggested that up-regulation of hTERT expression by low-dose cisplatin is NF-kappaB-dependent and contributes to chemotherapy resistance in human hepatocellular cancer cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Hepatocellular / drug therapy. Cisplatin / pharmacology. Liver Neoplasms / drug therapy. Telomerase / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Damage. Drug Resistance, Neoplasm. Gene Expression Regulation, Enzymologic. Humans. NF-kappa B / physiology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639202.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Li Q, Gao C, Juzi JT, Hao X: Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg; 2007 Apr;77(4):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of the study was to improve the diagnosis and treatment of retroperitoneal schwannoma by analysing clinical manifestations and postoperative course of this rare disease.
  • Only in 13 patients (15.9%) a correct preoperative diagnosis was made by either ultrasound-guided biopsy, computed tomography scanning or magnetic resonance imaging.
  • All patients received operative therapy.
  • Sixty patients (73.2%) underwent a total resection; 13 patients (15.9%) subtotal resection, but 9 patients (11.0%) had only an examination and a biopsy.
  • Pathological results showed 81 (98.8%) were benign schwannoma and 1 (1.2%) was a malignant one.
  • The patient with malignant schwannoma died 18 months after the operation because of metastasized disease.
  • However, with the preoperative assessment of ultrasound-guided fine-needle aspiration, computed tomography and magnetic resonance imaging, the accuracy of diagnosis could definitely be improved.
  • Treatment depends solely on surgery.
  • Malignant schwannomas are insensitive to chemotherapy and radiation, resulting in poor prognosis.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388825.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A: Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg; 2009;16(5):639-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: We present our experience in the treatment of nonfunctioning neuroendocrine pancreatic tumors (NFNPTs) to define the clinical and pathological characteristics and to suggest proper management.
  • METHODS: The records of 17 patients with NFNPTs operated on between 1998 and 2008 were retrospectively reviewed, and all tumors were classified clinicopathologically as benign, uncertain, and malignant, based on the World Health Organization (WHO) classification of neuroendocrine tumors.
  • RESULTS: There were four benign, six uncertain, and seven malignant NFNPTs.
  • Most of these symptomatic patients had malignant tumors.
  • Mean tumor size of benign, uncertain, and malignant tumors were 1.0 +/- 0.3, 3.2 +/- 1.6, and 5.3 +/- 2.4 cm, respectively.
  • Metastatic lesions of malignant tumors were lymph node (six patients), liver (four patients), and adrenal gland (one patient).
  • Six of seven patients with malignant tumors underwent curative rejection.
  • There were recurrences in four of six patients with curatively rejected malignant tumors.
  • Two patients underwent more rejection, three patients received systemic chemotherapy, and two patients underwent radiofrequency ablation and transcatheter arterial chemoembolization for liver metastases.
  • Survival of patients with malignant tumors was significantly shorter than that of patients with benign and uncertain tumors.
  • However, three patients with malignant tumors had long survival of more than 3 years, even with metastases or recurrences.
  • Even when a tumor was unresectable or there were recurrences, long-time palliation could be achieved by a multidisciplinary approach.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreatectomy / methods. Probability. Retrospective Studies. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365596.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Sperti C, Berselli M, Pasquali C, Pastorelli D, Pedrazzoli S: Aggressive behaviour of solid-pseudopapillary tumor of the pancreas in adults: a case report and review of the literature. World J Gastroenterol; 2008 Feb 14;14(6):960-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solid-pseudopapillary tumor (SPT) is a rare neoplasm of the pancreas that usually occurs in young females.
  • It is generally considered a low-grade malignant tumor that can remain asymptomatic for several years.
  • The tumor invaded a long segment of the portal-mesenteric vein confluence, and was removed with a total pancreatectomy, resection of the portal vein and reconstruction with the internal jugular vein.
  • The postoperative course was uneventful, but 32 mo after surgery the patient experienced diffuse liver metastases.
  • Chemotherapy with different drugs was started.
  • The best treatment remains a radical resection whenever possible, even in locally advanced or metastatic disease.
  • The role of chemotherapy, and/or radiotherapy, is still to be defined.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Middle Aged. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):887-9 [10919054.001]
  • [Cites] J Surg Oncol. 2007 Jun 15;95(8):640-4 [17477365.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Pancreatology. 2002;2(5):495-8 [12378119.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Ann Chir. 2003 Oct;128(8):543-8 [14559306.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):291-3 [15043751.001]
  • [Cites] J Surg Oncol. 1983 Feb;22(2):115-7 [6823124.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):272-5 [6830334.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2783-5 [4052952.001]
  • [Cites] Gastroenterol Jpn. 1987 Jun;22(3):379-84 [2442059.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):283-91 [2295051.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] Acta Pathol Jpn. 1991 Oct;41(10):763-70 [1812691.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Med Pediatr Oncol. 1993;21(5):365-7 [8492753.001]
  • [Cites] Surgery. 1995 Nov;118(5):821-8 [7482268.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(10):789-93 [9587521.001]
  • [Cites] Pathol Int. 1999 Mar;49(3):231-4 [10338079.001]
  • [Cites] Cancer. 1961 Nov-Dec;14:1272-94 [13909709.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):185-6 [15737835.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1403-9 [15761986.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):456-9 [16109536.001]
  • [Cites] Pathol Int. 2005 Dec;55(12):792-6 [16287495.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):276-82 [16457845.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):733-7 [16609955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1157-63 [16778826.001]
  • [Cites] Pancreatology. 2006;6(4):291-6 [16636602.001]
  • [Cites] JOP. 2006;7(6):635-42 [17095844.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):587-90 [17139438.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):639-40 [17149006.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):809-16 [17198473.001]
  • [Cites] JOP. 2007;8(2):223-7 [17356247.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):289-96 [11320522.001]
  • (PMID = 18240360.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687069
  •  go-up   go-down


19. Doval DC, Bhatia K, Pavithran K, Sharma JB, Vaid AK, Hazarika D: Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature. Hepatobiliary Pancreat Dis Int; 2006 May;5(2):305-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature.
  • Gallbladder metastases are very rare and usually arise from malignant melanoma, renal cell carcinoma and cervical carcinoma.
  • One month after the operation, she developed acute abdominal pain and underwent cholecystectomy after clinical investigation.
  • Being considered a patient with metastatic breast carcinoma she was subjected to taxane and anthracycline-based palliative chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Gallbladder Neoplasms / secondary. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698597.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  •  go-up   go-down


20. Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN: Mimics of cholangiocarcinoma: spectrum of disease. Radiographics; 2008 Jul-Aug;28(4):1115-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is the second most common primary malignant hepatobiliary neoplasm, accounting for approximately 15% of liver cancers.
  • A wide spectrum of neoplastic and nonneoplastic conditions of the biliary tract may masquerade as cholangiocarcinoma, adding to the complexity of management in patients suspected to have cholangiocarcinoma.
  • Mimics of cholangiocarcinoma constitute a heterogeneous group of entities that includes primary sclerosing cholangitis, recurrent pyogenic cholangitis, acquired immunodeficiency syndrome cholangiopathy, autoimmune pancreatitis, inflammatory pseudotumor, Mirizzi syndrome, xanthogranulomatous cholangitis, sarcoidosis, chemotherapy-induced sclerosis, hepatocellular carcinoma, metastases, melanoma, lymphoma, leukemia, and carcinoid tumors.
  • In most cases, a definitive diagnosis can be established only with histopathologic examination of a biopsy specimen.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / radiography. Carcinoma / diagnosis. Cholangiocarcinoma / diagnosis. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635632.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


21. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • METHODS: A retrospective search of our liver database was performed using the key words "pancreatico-duodenectomy", "chylous ascites" from January 2000 to December 2005.
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.
  • [MeSH-major] Chylous Ascites / diagnosis. Chylous Ascites / metabolism. Duodenum / surgery. General Surgery / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Pancreas / surgery
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Transplantation. Peritoneum / metabolism. Postoperative Complications. Retrospective Studies

  • Genetic Alliance. consumer health - Chylous Ascites.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Kitami CE, Shimizu T, Sato O, Kurosaki I, Mori S, Yanagisawa Y, Ajioka Y, Hatakeyama K: Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg; 2000;7(5):529-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant islet cell tumor projecting into the main pancreatic duct.
  • We report herein a rare case of islet cell tumor showing a unique growth pattern in a patient who developed repeated acute pancreatitis as the tumor's initial symptom.
  • A distal pancreatectomy with splenectomy was performed because the pancreatitis was localized in the distal pancreas and was not controlled by various drug therapies.
  • Grossly, the tumor consisted of two component parts: a markedly infiltrative part in the pancreatic parenchyma, and a papillary elevated part in the MPD.
  • The MPD was obstructed by the tumor spreading widely along the distal MPD.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreatectomy. Pancreatitis / etiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180883.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down






Advertisement